 |
인쇄하기
취소
|
Ilyang awaits approval for ilaprazole in China
Ilyang Pharm is soon expecting to receive marketing approval for ilaprazole, a new investigational proton pump inhibitor, from the Chinese drug regulatory agency (SFDA) after completing a local phase III clinical study.
Ilyang said that the phase III test was performed at 15 clinical test centers including the Medical College of University of Beijing very successfully, and found that Ilaprax...
Ilyang said that the phase III test was performed at 15 clinical test centers including the Medical College of University of Beijing very successfully, and found that Ilaprax...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.